Teva Launches Generic Cozaar/Hyzaar With Market Exclusivity As FDA Seeks Court Action To Permit Other Entrants
Executive Summary
Teva's skirmish with FDA has paid off. The company launched generic versions of Merck's top-selling hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide) on April 6 with 180 days of marketing exclusivity
You may also be interested in...
New Tactic In ANDA Litigation: Novo Blocks Generic Prandin By Changing Its Patent Use Code
Novo Nordisk succeeded in an unusual maneuver in blocking Caraco Pharmaceutical from getting a generic version of its blood glucose-lowering drug Prandin (repaglinide) on the market. It changed the use code on the patent covering the drug in combination with metformin so that Caraco could not get approval for a monotherapy
New Tactic In ANDA Litigation: Novo Blocks Generic Prandin By Changing Its Patent Use Code
Novo Nordisk succeeded in an unusual maneuver in blocking Caraco Pharmaceutical from getting a generic version of its blood glucose-lowering drug Prandin (repaglinide) on the market. It changed the use code on the patent covering the drug in combination with metformin so that Caraco could not get approval for a monotherapy
Teva's Generic Exclusivity For Cozaar/Hyzaar Is Upheld By District Court; Apotex Appeals
Court finds that FDA correctly followed an appeals court's reasoning in awarding Teva exclusivity; Apotex says the agency failed to make a distinction between patent delisting and expiration.